A meta-analysis summarizing data from 12 clinical trials in G/GEJ cancer found that ICI monotherapy did not provide survival benefits in the PD-L1 negative population, and its efficacy improved incrementally with increasing CPS [19]. Here, CD274 is linked to cancer.